Homing of chronic lymphocytic leukemia (CLL) cells to sites favoring growth, a critical step in disease progression, is principally coordinated by the CXCL12/CXCR4 axis. A cohort of 62 CLL patients was divided into migrating and nonmigrating subsets according to chemotaxis toward CXCL12. Migrating patients phosphorylated extracellular signal-regulated kinase 1/2 (ERK1/2) proteins more than nonmigrating patients (Po0.0002). CD38 expression was the parameter most strongly associated with heightened CXCL12 signaling (Po0.0001), confirmed by independent statistical approaches. Consistent with this observation, CD38
Introduction
Chronic lymphocytic leukemia (CLL) is characterized by the expansion of a monoclonal population of mature B lymphocytes expressing surface CD5, CD23 and low levels of immunoglobulin (Ig). 1 It accumulates in blood (the circulating pool) and in lymphoid organs (the residential pool). The phenotype of the cells present in the two pools differs significantly, likely reflecting tissue-specific effects and signals. Residential neoplastic lymphocytes express higher levels of surface molecules, which modulate interactions with neighboring T lymphocytes, stromal, endothelial and nurse-like cells. [2] [3] [4] [5] These interactions are deemed necessary for CLL proliferation; data obtained in patients suggest that the proliferative core of the disease dwells within the residential pool, whereas little or no proliferation is seen among circulating CLL cells. 6 This residential pool proliferative paradigm is associated with CD38 7, 8 and CD40, 9 two surface activatory receptors that are expressed at higher densities by CLL cells in bone marrow (BM) and lymph nodes than in blood. Human CD38 is a pleiotropic glycoprotein belonging to a complex family of genes coding for enzymes of the cell surface and involved in the catabolism of extracellular nucleotides. 10 During evolution, CD38 acquired the ability to mediate cell-cell interactions by binding the nonsubstrate ligand CD31, surrogated in vitro by IB4, an agonistic monoclonal antibody (mAb).
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CD31/CD38 interactions activate an intracellular signaling pathway that converges on the activation of the extracellular signal-regulated kinase 1/2 (ERK1/2) kinase in distinct lymphocyte populations and induce activation and proliferation as a final result. 12, 13 In clinical setting, CD38 expression above a critical threshold represents a reliable negative prognostic marker for CLL patients, 14 along with the absence of mutations in the Ig variable region heavy chain gene (IgVH) 15 and expression of the cytoplasmic kinase zeta-chain-associated protein kinase 70 (ZAP-70). 16 The working hypothesis of our group is that CD38 is not merely a marker, but a cell surface receptor and adhesion molecule directly involved in the delivery of proliferation signals. 17 CD38-mediated signals increase survival of the leukemic clone and sustain its growth in vitro. 18 The kinase ZAP-70 represents a necessary component in the molecular chain of events activated by CD38, providing a functional link for what were previously considered to be two independent negative prognostic markers. 19 Furthermore, CD38 þ /ZAP-70 þ CLL cells are characterized by enhanced propensity to migrate in response to CXCL12, 19 an essential chemokine in the recirculation of neoplastic cells between blood and the lymphoid organs. 20 The hypothesis behind this study is that CD38 represents a point of convergence of proliferation and migration signals. Results obtained by analyzing a large cohort of CLL patients, and confirmed using an in vivo mouse model, indicate an active role for CD38 in synergizing with the CXCR4 signaling pathway and in controlling chemotaxis/homing processes of CLL cells.
Materials and methods

Patients and cells
A total of 62 samples from CLL patients presenting with typical morphology and immunophenotype were obtained after obtaining written informed consent in accordance with the institutional guidelines and Declaration of Helsinki. Analyses included CD38 and ZAP-70 staining (cutoff positivity values of X20%), IgVH mutational status (unmutated if X98% homology to the germline gene) and fluorescence in situ hybridization for chromosomes 11, 12, 13 and 17 (Supplementary Table 1 ). B cells were purified from peripheral blood mononuclear cells (PBMCs) by negative selection. 19 The intraclonal CD38 À component of CLL samples with bimodal CD38 expression was obtained by incubation with anti-CD38 mAbs and magnetic bead separation. The Nalm-6 cell line (CD38 þ /CXCR4 þ / ZAP-70 dim ) was obtained from DSMZ (Braunschweig, Germany).
Antibodies and reagents
Anti-CD38 mAbs were IB4, SUN-4B7, IB6, AT-1, AT13/5, HB-7 and OKT10. Irrelevant mAbs were anti-gp120 and anti-HLA Class I. All these reagents were purified in-house. The blocking anti-CXCR4 mAb (clone 12G5) was from R&D Systems (Milan, Italy). Anti-phospho-ERK1/2 and anti-pan-ERK were from BDBiosciences (Milan, Italy). Goat anti-mouse IgG-HRP-conjugated (Perkin Elmer, Milan, Italy) was used as secondary antibody (Ab) in western blot analysis. When indicated, IB4 mAb was cross-linked using a donkey anti-mouse IgG Ab (DaMIgG, Southern Biotechnology, Birmingham, AL, USA). CD5-FITC and CD19-PE were from Immunostep (Salamanca, Spain), CD45-PerCP was from BD-Biosciences. Recombinant human CXCL12 was from R&D Systems.
ERK1/2 phosphorylation studies
Extracellular signal-regulated kinase 1/2 phosphorylation was determined by exposing CLL cells (8 Â 10 6 ) to IB4 mAb (1 mg per 10 6 cells) or CXCL12 (1 or 10 ng per 10 6 cells) for the indicated time points at 37 1C. Excess IB4 was removed by washing and cells were cross-linked with a DaMIgG (10 mg per 10 6 cells) before transfer at 37 1C. Total lysates were resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis and analyzed by western blot (18 mg proteins per lane). Densitometric analyses were performed using the NIH ImageJ software (http:// rsbweb.nih.gov/ij/). Percent increase in ERK1/2 phosphorylation (p-ERK1/2) was calculated as: ((p-ERK1/2 band intensity of treated cells/p-ERK1/2 band intensity of untreated cells) Â 100) and standardized to 100 (maximum value obtained on CXCL12 exposure). Blocking experiments were performed by preincubation (20 min on ice) of cells with anti-CD38 (SUN-4B7), anti-CXCR4 (12G5) or anti-gp120 mAbs, all at 5 mg per 10 6 cells. Unbound mAbs were removed before exposure to CXCL12 (10 ng per 10 6 cells). Percent inhibition in p-ERK1/2 phosphorylation was calculated as: (100À(p-ERK1/2 band intensity of relevant mAb-treated cells/p-ERK1/2 band intensity of cells without mAb treatment Â 100)).
Chemotaxis assay
Chemotaxis assays to CXCL12 (60 ng per 10 6 cells per well) were performed in the Boyden chamber. 19 When indicated, CLL cells (10 6 cells per well) were incubated (30 min, 4 1C) with purified anti-CXCR4 (5 mg per 10 6 cells), anti-CD38 or anti-HLA Class I mAbs (both at 6 mg per 10 6 cells), and unbound mAbs were removed by washing. The number of migrated CLL cells was determined by subsequent staining with anti-CD19-PE and anti-CD5-FITC. The migration index (MI) was calculated as the ratio between the number of CD5 þ /CD19 þ cells transmigrating in the presence and absence of CXCL12. Percent inhibition of migration was calculated as (100À(MI of treated cells with the indicated blocker/MI of untreated cells Â 100)) and standardized to 100 (maximum MI among the cohort of patients analyzed). Experiments were carried out in duplicate, measuring chemotaxis in two separate wells for each condition.
Generation of lentiviruses and infection
Lentiviral particles containing the genetic material for CD38 were generated as described 21 and designated as S38W. The green fluorescent protein (GFP) virus (SEW), driven by the same promoter, has been previously described and used as control. 22 Freshly purified or thawed PBMC preparations from CLL patients were plated (10 6 cells per ml) in RPMI-1640 medium þ 10% fetal calf serum (Seromed, Berlin, Germany) in the presence of concentrated viral particles and incubated for 48 h at 37 1C. Viral particles were titrated as described 21 to obtain levels of CD38 expression comparable with those commonly observed in CLL patients.
Immunoprecipitation studies
Cells (50 Â 10 6 CLL cells) were lysed (1% NP-40), pre-cleared with protein A þ G agarose (Sigma, Milan, Italy) and incubated with anti-CD38 (OKT10), anti-CXCR4 (rabbit polyclonal Ab against the N-terminus, Millipore, Vimodrome, Italy) or irrelevant X63 mAb (0.2 mg mAb per 100 mg lysate for 4 h at 4 1C) followed by protein G plus agarose (30 ml dry pellet, Santa Cruz Biotechnology, DBA Italia, Segrate, Italy). Immunoprecipitates were resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis under nonreducing conditions and analyzed by western blot. CD38 was visualized using SUN-4B7 mAb and CXCR4 by a rabbit polyclonal Ab specific for the second extracellular loop (AbD Serotec, Milan, Italy).
Confocal microscopy
Cells (5 Â 10 5 CLL cells) were treated with CXCL12 (50 ng per 10 6 cells, 37 1C), fixed (2% paraformaldehyde, 10 min) and permeabilized (0.1% saponin, 10 min). Cells were stained for CD38 (saturating AT-1 mAb þ titrated Alexa-488-goat antimouse IgG (Invitrogen, Milan, Italy)) and CXCR4 (biotinylated mAb þ Alexa-568-streptavidin (Invitrogen)). Cells were analyzed with a two-laser Olympus (Milan, Italy) 1X71 confocal microscope, using the FluoView software (Olympus, Milan, Italy). Images were processed using Adobe Photoshop CS3 software (www.adobe.com).
Nonobese diabetic severe combined immunodeficiency homing model
Peripheral blood mononuclear cells from CLL patients (25 Â 10 6 , 480% leukemic cells) or 12.5 Â 10 6 Nalm-6 cells were incubated (30 min, 4 1C) with anti-CD38 (SUN-4B7 or OKT10, both at 6 mg per 10 6 cells) or anti-CXCR4 mAbs (5 mg per 10 6 cells) before intravenous injection in female nonobese diabetic severe combined immunodeficiency mice (8-15 weeks old). Spleen and BM were recovered 18-20 h after injection, reduced to single cell suspensions and incubated with anti-CD45-PerCP, anti-CD5-FITC and anti-CD19-PE. Anti-CD19-PE was used for Nalm-6 cells. At least three mice were analyzed for each condition. Animal use was approved by the Italian Ministry of Health. Cells (1.5 Â 10 6 ) were acquired by flow cytometry; morphological acquisition parameters (forward scatter, 1.49 and side scatter, 381) were constant for each experiment. Fluorescence cutoffs and compensation was determined on the basis of staining-purified PBMC preparations or Nalm-6 cells. Data from CLL samples were analyzed using the software WinMDI 2.9 (http://facs.scripps.edu/software.html) by gating on lymphocytes (R1) and then on CD45 þ cells (R2). CD19/CD5 fluorescence levels were determined for cells in R3 (R1 Â R2). Percent homing inhibition was calculated as: (100À(number of leukemic cells in spleen or BM of mice injected with untreated cells/number of leukemic cells in spleen or BM of mice injected with treated cells Â 100)).
Statistical analysis
Student two-sample, two-tailed t-test was used to compare continuous variables. The correlation between continuous variables was assessed by measuring the Spearman's correlation coefficient.
Results
Functional responses to CXCL12 are higher in CD38 þ
CLL patients
Recirculation of CLL cells from blood to the lymphoid organs, an essential step in leukemia progression, is principally coordinated by the CXCL12 chemokine. Acute effects exerted by CXCL12 on CLL cells prototypically include activation of ERK1/2, whereas the final outcome of protracted chemokine exposure is migration, measurable in vitro using the Boyden chamber. 23 These two indicators were adopted to test functional responses to CXCL12 in a cohort of 62 CLL patients (Supplementary Table 1 ). ERK1/2 activation was quantified in 34 patients after exposure to a fixed amount of chemokine (10 ng per 10 6 cells for 2 min), whereas a MI was determined for 58 patients; 30 patients could be evaluated for both parameters.
When considered as continuous variables, MI and ERK1/2 phosphorylation showed a positive correlation (Spearman's r ¼ 0.396, P ¼ 0.030, Supplementary Figure 1A) . A cutoff value of 20 was arbitrarily adopted for the MI; patients with MIX20 were considered migrating. Using this cutoff, migrating patients displayed ERK1/2 proteins phosphorylated at significantly higher levels than nonmigrating patients (Po0.0001, Figure 1a ), in line with the view that ERK1/2 activation is a critical step in the CXCL12 pathway. 24, 25 Migrating and nonmigrating CLL patients did not display measurable differences in CXCR4 expression, either in terms of percentage of positive cells (Spearman's r ¼ À0.148; P ¼ 0.285, t-test: P ¼ 0.98) or of mean fluorescence intensity (Spearman's r ¼ À0.100; P ¼ 0.473, t-test: P ¼ 0.93), Figure 1D ). Consistently, all migrating CLL patients of this cohort featured CD38 expression of X20% clinical threshold. The nonmigrating subset of patients had heterogeneous CD38 expression levels, with overall mean values significantly lower than the migrating subset (Po0.0001, Figure 1d ). Furthermore, a significant association was found between MI and ZAP-70 expression either when considered as continuous variables (Spearman's r ¼ 0.294, P ¼ 0.026, Supplementary Figure 1E ) or after stratification according to the MI cutoff value of 20 (P ¼ 0.02, Figure 1e) . A trend toward significance was observed when examining the percentage of mutations in the IgVH genes (Spearman's r ¼ 0.204, P ¼ 0.101; t-test: P ¼ 0.10, Figure 1f and Supplementary Figure 1F) . No associations were highlighted with the common cytogenetic abnormalities (not shown). Thus, CD38 expression is the single parameter that best associates with heightened chemotactic responses to CXCL12. The same conclusions hold when examining ERK1/2 (Supplementary Figure 2 ).
These observations suggest the existence of a preferential association between migration in response to CXCL12 and expression of CD38. The selective enrichment in the percentage of CD19 þ /CD38 þ cells observed in the lower section of the Boyden chamber compared with the basal expression of CD38 in 10 different patients supports the view that the CD38 þ subset migrates more (Figure 2a ). Further evidence in favor of this hypothesis was obtained by studying CLL patients with bimodal CD38 expression. These clones, reported as monoclonal in origin, 26 offered the potential for investigating the biological effects exerted by CXCL12 in CD38 þ and CD38 À cells against a homogeneous genetic background. The decision to separate the CD38 À component by negative selection and compare it with the intact clone was dictated by the need to avoid any manipulation of the cells before functional experiments. The CD38 À cell component of these patient samples was less responsive to CXCL12 signaling in terms of ERK1/2 phosphorylation (Figure 2b and c) and chemotaxis (Figure 2d ). Furthermore, the CD38 À component showed a low but constant presence of a constitutively activated p-ERK1/2 band, likely reflecting basal activation of these cells. The different responses to CXCL12 could not be attributed to CXCR4 expression; these were comparable in terms of percentage of positive cells and receptor density in CD38 þ and CD38 À sub-populations derived from the same patient (Figure 2e ).
De novo insertion of the CD38 gene in CD38
À CLL cells increases sensitivity to CXCL12
To formally link expression of CD38 to functional responses to CXCL12, CD38
À CLL cells were genetically modified to express the molecule. 21 Infection with lentiviruses carrying the genetic material for CD38 was followed by increased CD38 expression in 11 of 14 (Po0.0001, 78%) patients studied. The increase was only moderate to minimal in the remaining three patients, with the percentage of CD38 þ cells not reaching the 20% clinical cutoff (Figure 3a) . The 48-h incubation time was selected as the earliest time point with maximal CD38 induction (not shown). Viruses carrying a GFP plasmid were titrated in a similar way and used as controls (Figure 3a) . The phenotype of the infected cells remained stable in terms of CD19 and CD5 expression, and in the percentage (not shown) and mean fluorescence intensity (Figure 3b ) of CXCR4. Representative dot-blots are shown in Figure 3c .
De novo expression of CD38 was accompanied by increased ERK1/2 phosphorylation (Figure 3d and e, n ¼ 4) as well as chemotactic responses (Figure 3f , n ¼ 14) in the presence of CXCL12 in 11 of 14 patients studied. The 3 of 11 nonresponding patients were those in whom the induction of CD38 expression after infection was below the 20% cutoff. Infection with the GFP virus did not modify CD38 expression as well as ERK1/2 phosphorylation levels and the MI, which remained comparable with the values scored by cells kept in culture for the same amount of time. The p-ERK1/2 levels and MI values of samples cultured in complete medium for 48 h was significantly increased as compared with the baseline (Figure 3d-f ), in line with previous results. 27 
Anti-CD38 mAbs modulate CXCL12 responses
The next question was whether CD38 signals can directly influence short-and long-term CXCL12 responses. Ligation of CD38 with the agonistic IB4 mAb is known to start a signaling pathway in distinct cell lineages and derived models, 10 including CLL.
28 ERK1/2 is a molecular target shared by the signaling pathways controlled by CD38 and CXCR4. As expected, CD38 ligation with the IB4 mAb induced variable degrees of ERK1/2 phosphorylation, starting after 30 s, peaking at 2 min and declining rapidly after 5 min (Figure 4a) . A similar, although stronger ERK1/2 activation was induced by CXCL12 exposure, with the signal becoming apparent after 30 s and declining slowly over 60 min (Figure 4b ). Exposure to CXCL12 in the presence of the agonistic anti-CD38 mAb led to a significant increase in the amount of phosphorylated ERK1/2 proteins and to the anticipation of the signal, already prominent after 30 s (Figure 4c ). These synergistic effects were concordant in the four patients tested (Figure 4d) .
The exposure to CXCL12 in the presence of the agonistic anti-CD38 mAb produced an increase in chemotactic responses, as witnessed by a significant rise in the MI apparent in five of five CD38 þ patients tested (Figure 4e , P ¼ 0.003). The binding of an isotype-matched anti-HLA Class I mAb, a highly expressed molecule but inert in this system and used as control, did not influence chemotactic responses. On the contrary, the blocking anti-CXCR4 mAb significantly inhibited chemotaxis, as expected (Figure 4e , Po0.001). The effects of the agonistic mAbs were dose-dependent, with the maximum increase scored at 5 mg per 10 6 cells (not shown). If CD38 activation is followed by heightened functional responses to CXCL12, then blocking CD38 should result in decreased CXCL12 signals. Experiments were performed using a panel of six known nonagonistic anti-CD38 mAbs (namely, SUN-4B7, AT-1, AT13/5, IB6, HB-7 and OKT-10) and measuring the chemotactic responses of samples derived from five different CLL patients. The results clearly indicated that two mAbs exert statistically significant blocking activities, one had mild blocking potential and three were uninfluential (Figure 4e) . The SUN-4B7 mAb was selected as the best blocking reagent and further used in subsequent studies, whereas the OKT10 mAb was adopted as the irrelevant and isotype-matched (IgG 1 ) mAb.
Blocking anti-CD38 mAbs inhibit CXCL12 responses in vitro
The functional influence exerted by the blocking anti-CD38 mAb on the CXCR4 signaling pathway was investigated on CD38 regulates chemotaxis of CLL cells T Vaisitti et al short-term signaling events. Pre-incubation of CLL lymphocytes obtained from three different CD38 þ CLL patients with the anti-CD38 mAb SUN-4B7 significantly inhibited ERK1/2 phosphorylation levels, with effects apparent after 2 min of CXCL12 exposure and persisting thereafter (Figure 5a ). The inhibition of phosphorylation mediated by anti-CD38 mAbs was comparable in all samples. Blocking anti-CXCR4 mAb exerted more pronounced effects. On the contrary, the isotype-matched irrelevant anti-gp120 mAb did not significantly influence ERK1/2 phosphorylation. The results were pooled together confirming a statistically significant inhibition of phosphorylation after incubation with anti-CD38 and with control anti-CXCR4 mAb (Figure 5b ). No block in phosphorylation was observed when considering CD38 À CLL samples (n ¼ 2, not shown). The same effects were observed in Nalm-6 cells (not shown), a CD38 þ /CXCR4 þ cell line selected as model for standardization purposes.
The blocking effects of anti-CD38 mAbs on chemotaxis were further tested in vitro using a larger cohort of characterized CLL patients. Pre-treatment of PBMC suspensions (n ¼ 14) with the þ /CD38 þ cells in PBMC preparations of 10 CLL patients (basal) and in the lower section of the transwell after 4 h chemotaxis using CXCL12 (60 ng per 10 6 cells per well) as attractant (lower) (a) The CLL cells that respond to CXCL12 are increased in the percentage of CD38, suggesting that the CD38 þ subset within the same CLL clone migrates more. Early (ERK1/2 activation) and late (chemotaxis) events in response to CXCL12 were studied in six CLL patients with bimodal CD38 expression. The CD38 À component is less responsive than the intact clone in terms of ERK1/2 phosphorylation ((b) one representative patient sample is shown and (c) cumulative data obtained from three distinct patients) and chemotaxis (d). CXCR4 expression is comparable in both subsets (e). Lines connect data points for the MI of individual patients in a, d and e.
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anti-CD38 mAb SUN-4B7 resulted in a significant reduction of chemotaxis of leukemic cells, defined on the basis of CD19/CD5 coexpression ( Figure 5c ). The effects were specific for CD38 þ samples; migration was not affected when the same anti-CD38 mAbs were used to treat CD38 À CLL cells (n ¼ 6, Figure 5d ), ruling out the role of IgG ligands. Blocking anti-CXCR4 mAb showed the highest degree of inhibition, regardless of surface CD38 expression levels. The control anti-HLA Class I mAb did not interfere with migration in either patient subgroup (Figure 5c and d). mAb titration was performed using Nalm-6 cells. Anti-CD38 and anti-CXCR4 mAbs blocked chemotaxis with comparable efficiency, with the highest inhibitory effects obtained with 6 mg per 10 6 cells and 5 mg per 10 6 cells, respectively (Supplementary Figure 3) .
Molecular interactions between CD38 and CXCR4
The blocking effects exerted by blocking anti-CD38 mAbs might therefore be explained if the two receptors are physically close on the membrane. To address this, we immunoprecipitated CD38 using the OKT10 mAb from NP-40 lysates derived from three CLL samples. Detection in western blot with the SUN-4B7 mAb, which is specific for a different CD38 epitope, invariably highlights a B43 kDa single chain and a B45 kDa molecule reactive with an anti-CXCR4 polyclonal Ab. Reversing the sequence, immunoprecipitation with a different anti-CXCR4 polyclonal Ab also precipitated a protein of B43 kDa, detected by the SUN-4B7 anti-CD38 mAb. No interaction was seen using an irrelevant mAb. These results indicate that a proportion of CD38 is associated with CXCR4 under basal conditions (Figure 5e ). 
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Physical interactions were next analyzed in live CLL cells by confocal microscopy. The results indicate that CD38 and CXCR4 are localized in the same membrane patches in basal conditions (that is, cells used immediately after purification). CXCL12 administration is rapidly (5-20 min) followed by reorganization of the membrane, with the appearance of marked protrusions (Figure 5f ). In alignment with previous reports, a fraction of CXCR4 re-localizes within these structures, revealing the molecule at the leading edge of the cell. 29 Conversely, CD38 molecules remain on the main cellular body; under these experimental conditions, CXCR4 and CD38 partially dissociate after CXCL12 exposure. At a later stage (60 min), a fraction of the CXCR4 molecules is internalized (white arrows, Figure 5f ), whereas the CD38 molecules remain on the cell surface.
These results indicate that a fraction of CD38 and CXCR4 display privileged associations on the surface of circulating CLL cells. The association is dynamic and regulated by CXCL12.
Blocking anti-CD38 mAbs block CLL homing in vivo
These results were transferred to an in vivo model to study the influence of CD38 on homing of CLL cells from blood to the lymphoid organs, an event critically controlled by CXCL12. 30, 31 Homing of CLL cells from blood to spleen and BM was analyzed using a nonobese diabetic severe combined immunodeficiency mouse model, with leukemic cells injected into the tail vein. After 18-20 h, mice were killed and human cells were tracked in the spleen and BM by staining with specific anti-human reagents. The optimal conditions were set up using Nalm-6, the cell line initially exploited for these experiments. 30, 31 Intravenous injection of Nalm-6 cells was followed by homing to spleen and BM. Homing was significantly reduced when human cells were pre-incubated with the blocking anti-CD38 mAb (SUN-4B7) immediately before in vivo delivery. The effect was more marked in spleen than in BM. No inhibition was observed when using isotype-matched anti-CD38 mAbs (OKT10 and HB-7), which did not interfere with CXCR4 pathway in vitro, suggesting that the effect is not due to sequestration of mAb-coated cells. As expected, blocking anti-CXCR4 mAb led to an almost complete block in homing to both districts (Figure 6a) . The same experimental approach was then applied to PBMCs freshly purified from CLL patients. In this instance, CLL lymphocytes were identified from spleen and BM samples by morphological gating and triple staining with anti-humanspecific CD45/CD19/CD5 mAbs (Figure 6b ). CLL lymphocytes migrated markedly better than Nalm-6 cells to both sites. Out of the eight patients analyzed, two showed reduced constitutive homing: these patients were CD38
þ /ZAP-70 À (Supplementary  Table 2 ), in line with previous data indicating that ZAP-70 is a limiting factor in CD38 signaling pathway. 19 The spleen was the favored target organ for CLL, as it was for Nalm-6. Preincubation with SUN-4B7 anti-CD38 mAb constantly resulted in a statistically significant block of homing of CLL lymphocytes to both lymphoid organs. On the contrary, pre-treatment with an isotype-matched nonblocking anti-CD38 mAb (OKT10) did not provide significant effects. Control anti-CXCR4 mAb produced the expected blocking effects (Figure 6b and c and  Supplementary Table 2) . Figure 5 Pre-incubation of purified CLL cells with blocking anti-CD38 (SUN-4B7) or anti-CXCR4 mAbs before exposure to CXCL12 results in a significant inhibition of ERK1/2 phosphorylation. The isotype-matched irrelevant anti-gp120 mAb was used as the control (a). The intensities of p-ERK1/2 bands obtained from three different experiments were quantified and the percentage of inhibition calculated as described (b). Pre-treatment with SUN-4B7 was followed by a significant inhibition of chemotaxis in 14 CD38 þ CLL patients (c). Migration was not affected when the same anti-CD38 mAb was used to treat CD38 À CLL cells (n ¼ Homing of freshly purified PBMCs from CLL patients was studied using the same model. Data were analyzed by morphological gating on lymphocytes (R1) and subsequently on the CD45 þ subset (R2). The CD19/CD5 fluorescence levels were then determined for cells contained in R3 (R1 Â R2). (c) Pre-incubation with blocking anti-CD38 mAb (SUN-4B7) negatively interferes with homing of CLL lymphocytes to spleen and BM. Anti-CXCR4 mAb was used as the positive control, whereas an isotype-matched (IgG 1 ) anti-CD38 mAb (OKT10) was used as a binding but nonblocking control mAb. Results are presented as mean ± s.e.m. of eight independent experiments, with each condition analyzed in duplicate.
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Discussion
Signals from the microenvironment make essential contributions to the progression of hematopoietic and epithelial malignancies. An active crosstalk between cancer cells and neighboring nonneoplastic cells can modulate the aggressiveness of the tumor and its response to treatment. 32 CLL cells seem to be exquisitely sensitive to signals and conditions coming from the microenvironment, as their behavior can switch from resistance to apoptosis to active proliferation by trafficking from blood to lymphoid organs. Within tissues, proliferating CLL cells organize in structures termed pseudofollicles or proliferation centers, which are a typical finding of the disease. 33 Thus, CLL cells that can leave the blood and localize to favorable environments proliferate and give rise to a clinically aggressive disease. There is growing in vitro 20 and in vivo 34 evidence suggesting that the CXCL12/CXCR4 pathway is responsible for homing to privileged microenvironments.
The analysis of chemotactic responses to CXCL12 in a cohort of 62 characterized CLL patients using two independent statistical approaches showed that the ability to migrate is a highly heterogeneous trait and that it does not correlate with either the percentage or the intensity of expression of CXCR4. A clear-cut correlation with the presence of phosphorylated ERK1/2 bands was apparent, with ERK1/2 being activated in all patients featuring an MIX20, confirming in the CLL model that (i) ERK1/2 is a necessary element of the CXCR4 cascade and that (ii) it is a target shared with the CD38 pathway. Among the commonly used molecular parameters for predicting prognosis, the most significantly associated parameter with a high chemotactic response was CD38 expression: all migrating CLL patients were CD38 þ using the X20% clinical cutoff. Indirect confirmation of this preferential association was obtained by conventional chemotaxis assays showing a selective increase in the percentage of CD38 þ CLL cells in the lower section of the Boyden chamber, confirming the fact that the migrating population was CD38 þ . Furthermore, the CD38 À component of CLL clones with bimodal CD38 expression was significantly less responsive to CXCL12 in terms of ERK1/2 phosphorylation and chemotaxis than the intact clone, in spite of comparable expression levels of CXCR4. The CLL clones with bimodal CD38 expression were reported to derive from a single malignant transforming event and to be characterized by the same chromosomal abnormalities, 26 ruling out differences due to a heterogeneous genetic background. Lastly, infection of CLL cells with lentiviral particles carrying CD38 genetic material was followed by the acquisition of CD38 surface expression and by a significant increase in early and late functional responses to CXCL12. In contrast, no variation in CD38 expression was observed using a GFP control vector.
The biological explanation behind the association between CD38 and a negative clinical course may be found, at least in part, in the receptor-like features of the molecule. Previous reports helped to establish the fact that interaction between CD38 and CD31 ligand expressed by neighboring cells and surrogated in vitro by the agonistic mAb initiate a signaling pathway that enhances proliferation and prolongs survival of CLL lymphocytes. 13 Now, we show that ligation of CD38 using the same agonistic mAb directly facilitates CXCL12 signaling, suggesting that interactions between CD38 þ CLL cells and CD31 þ neighboring cells would modulate the competence of the leukemic clone to grow and progress in response to a chemokine-rich microenvironment. Independent immunohistochemical studies on lymph node sections revealed a direct association between the number of endothelial cells (CD31 þ ) and the level of CD38 expression by CLL cells, 8 indirectly confirming that CD31/CD38 static interactions occur in vivo. Moreover, the percentage of CD38 þ CLL cells 35, 36 and the density of tumor vessels 37, 38 correlate with neoplastic proliferation and disease aggressiveness.
In agreement with the view that CD38 signals synergize with the CXCR4 pathway, blocking CD38 by means of specific mAbs inhibited the short-and long-term effects of CXCL12. A likely explanation behind the blocking activity of these mAbs lies in the physical proximity of CD38 and CXCR4; accordingly, mAb binding to specific domains of CD38 would reduce accessibility of CXCR4 to the CXCL12 ligand. The existence of a CD38/ CXCR4 complex was shown by (i) coimmunoprecipitation and (ii) confocal microscopy studies. These results are supported by many reports in the field showing that human CD38 establishes supramolecular complexes with signaling receptors, adhesion molecules, other ectoenzymes (reviewed in Malavasi et al. 10 ), andFthis paperFchemokine receptors. Independent findings from the field of human immunodeficiency virus (HIV) research indirectly support the view of a CD38/CXCR4 supramolecular complex. Indeed, CD38 expression partially prevents HIV-1 infection due to the homology between the membrane proximal domain of CD38 and a distinct region of the gp120 HIV-1 envelope protein. 39 The results of the present study may fit the model, indicating that CD38/CXCR4 physiological interactions account for reduced accessibility of CXCR4 to HIV-1, thus limiting infection.
The relevance of these results was substantiated using an in vivo mouse model, in which CLL cells were allowed to home to lymphoid organs for a short period of time. This model was originally set up to study homing of blasts from acute lymphoid and myeloid leukemia patients. 30, 31 Long-term engraftment of human leukemic cells in the immunodeficient mouse environment was independently shown by different groups, 40, 41 clearly indicating that there is a hybrid crosstalk between adhesion molecules and signals coming from the two species. The compromised homing ability of CLL cells to spleen and BM in the presence of blocking anti-CD38 mAbs confirms in vivo the in vitro evidence. Furthermore, the lack of effects induced by an isotype-matched mAb with the same anti-CD38 specificity convincingly rules out the possibility that the effects observed are secondary to sequestration of mAb-coated cells.
Overall, these data confirm the association between CD38 and a migratory behavior of CLL cells, and a direct functional cooperation between CD38 and CXCR4 signaling pathways. Future studies are underway to support the working hypothesis that migration is a central step in disease progression and may help design a therapeutic approach.
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